Management & Regulatory

Thermo Fisher to Open Advanced Bioprocess Center in Hyderabad
Management & Regulatory Thermo Fisher to Open Advanced Bioprocess Center in Hyderabad

Thermo Fisher Scientific is making significant strides in the Indian biopharma market with the announcement of a new bioprocess design center (BDC) in Genome Valley, Hyderabad. This 10,000 square-foot facility, expected to open early next year, is part of a broader initiative by the company to

Is Sanofi’s Shift to Pure Biopharma the Future of Healthcare Innovation?
Management & Regulatory Is Sanofi’s Shift to Pure Biopharma the Future of Healthcare Innovation?

In October 2023, Sanofi, a leading global pharmaceutical company, announced a major shift in its business strategy. This shift involved the separation of its consumer health division, a move set to be completed in 2024. Historically, Sanofi's consumer health division, which includes popular

Fujifilm Diosynth To Expand Hillerød Facility, Adding 2,200 Jobs
Management & Regulatory Fujifilm Diosynth To Expand Hillerød Facility, Adding 2,200 Jobs

Fujifilm Diosynth Biotechnologies, a leading CDMO in the field of biologics, vaccines, advanced therapies, and oncolytic viruses, has embarked on the initial phase of a massive expansion project at their facility in Hillerød, Denmark. By adding six mammalian cell bioreactors to the existing

How Can Unified RIM Solutions Transform Biopharma Regulatory Processes?
Management & Regulatory How Can Unified RIM Solutions Transform Biopharma Regulatory Processes?

In the ever-evolving landscape of biopharmaceuticals, companies face the immense challenge of managing regulated data and documents, which has become more complex due to the surge in global regulations. The increasing necessity for a unified Regulatory Information Management (RIM) solution that

October 2024 Sees Record Biotech Investments Focused on Oncology
Management & Regulatory October 2024 Sees Record Biotech Investments Focused on Oncology

October 2024 saw a surge in biotech investments, with notable contributions from companies across North America, Europe, and the Asia-Pacific regions. Major players like Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics secured substantial funding, reflecting the growing

Is Arbutus Biopharma Positioned for Significant Growth Potential?
Management & Regulatory Is Arbutus Biopharma Positioned for Significant Growth Potential?

Recent developments and analyst perspectives have spotlighted Arbutus Biopharma (NASDAQ: ABUS), indicating a promising growth trajectory for this biopharmaceutical company. Chardan Capital's recent decision to raise its target price for Arbutus Biopharma from $4.00 to $4.50 signifies a

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later